Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors

Part of paid clinical trials in Los Angeles, California.

Sponsor
Zai Lab (Shanghai) Co., Ltd.
Study ID
NCT07374848
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Sarcomas
  • Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • ZL-6201 — DRUG
    ZL-6201 as a single-agent

Study Details

The purpose of this study is to evaluate the safety and tolerability of investigational study drug ZL-6201 for treating sarcoma and solid tumors cancer.

Key Dates

Start date
Mar 2, 2026
Status verified
Feb 2026
Primary completion
Aug 31, 2028
Completion
Sep 30, 2029

Study Design

Enrollment
180 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: ZL-6201
    ZL-6201 as a single agent

Primary Outcome Measure

Incidence of Dose Limiting Toxicities [ Time Frame: 1 cycle of study treatment (each cycle is 21 days) ]

Central Contacts

Locations (5)

FacilityCityStateZIPSite coordinators
Zai Lab Site 02003Los AngelesCalifornia90007-
Zai Lab Site 02026SarasotaFlorida34232
Site 02026
Zai Lab Site 02005St LouisMissouri63160-
Zai Lab Site 02002New YorkNew York10065-
Zai Lab Site 02006FairfaxVirginia22031
Site 02006

Find similar trials in Los Angeles, CA

By research site
Zai Lab· Los Angeles, CAZai Lab· Sarasota, FLZai Lab· St Louis, MOZai Lab· New York, NYZai Lab· Fairfax, VA

Related Studies